# NUMAFERM

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/numaferm

- Industry: Biotechnology
- Headquarters: Dusseldorf, Germany
- Website: www.numaferm.com
- Latest round: Seed (Sep 18, 2017)
- Investors on record: 3

## About

NUMAFERM GmbH is a biotechnology company focused on producing peptides, proteins, and pepteins utilizing advanced platforms like Numascreen™ and Numatech™.Founded in 2017 in Dusseldorf, Germany, Numaferm GmbH specializes in creating high-diversity phage display libraries for applications in pharmaceuticals, agriculture, and aquaculture. Philipp Buerling is the founder, with Christian Schwarz serving as CEO. The company raised seed financing in May 2017 led by Evonik Venture Capital, alongside participation from the European Investment Fund and High-Tech Gründerfonds.NUMAFERM GmbH specializes in the production of peptides, pepteins, and proteins through its innovative platforms, namely Numascreen™ and Numatech™. The core offering encompasses high-diversity phage display libraries that exceed 1 billion peptides, facilitating the discovery and optimization of high-affinity binders tailored for various applications. The Numatech™ platform ensures rapid large-scale peptide expression and timely delivery of high-quality products, serving a diverse customer base including pharmaceutical companies and agricultural firms primarily in Europe and North America.Numaferm generates revenue through structured partnerships and commercial agreements, particularly in the pharmaceutical and agricultural sectors. Their business model includes B2B contracts for lead discovery services and peptide production, often involving fixed pricing for specific projects or milestone-based payments. Their flagship products, such as Teriparatide and the proprietary Numascreen™ phage display libraries, are pivotal to their revenue streams, supported by strong client relationships and ongoing collaborations.Numaferm plans to introduce new products in the coming years, expanding its offerings within the peptide and protein markets. The company aims to penetrate new geographical regions, focusing on growth in Asia and South America by 2025. Recent funding from the Seed round will support these initiatives, enhancing their product development capabilities and enabling strategic market expansions.

## Funding rounds

- Seed, Sep 18, 2017 — European Investment Fund, High-Tech Gruenderfonds, Evonik Venture Capital

## Investors

- European Investment Fund (https://capitalatlas.ai/funds/european-investment-fund) — Seed
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed
- Evonik Venture Capital (https://capitalatlas.ai/funds/evonik-venture-capital) — Seed